ADVERTISEMENTs
_page-0001.jpg)
US FDA's top vaccine official Vinay Prasad leaves agency after 3 months
Prasad, an oncologist who was a fierce critic of U.S. COVID-19 vaccine and mask mandates, had been appointed in May by FDA Commissioner Marty Makary.
-
Reuters - Wed, 30, Jul 2025
- 23:58 EDT
- 37
.jpg)
Vinay Prasad. / LinkedIn/Vinay Prasad
The U.S. Food and Drug Administration's top vaccine official, Vinay Prasad, has left the agency after just three months as Director of the Center for Biologics Evaluation and Research, a government spokesperson said.
Prasad, an oncologist who was a fierce critic of U.S. COVID-19 vaccine and mask mandates, had been appointed in May by FDA Commissioner Marty Makary. Together they had promised to speed regulatory action and pilot new review pathways.
In recent days, criticism of Prasad's tenure has intensified around the agency's handling of a gene therapy for Duchenne muscular dystrophy from Sarepta Therapeutics (SRPT.O)
The FDA-approved therapy played a role in the death of two teens who had advanced disease, and after a third death in a separate experimental gene therapy from the company, the FDA on July 18 asked Sarepta to stop all shipments of the approved DMD therapy, saying it had safety concerns.
Laura Loomer, a far-right activist and President Donald Trump ally, on July 20 posted a blog in which she called Prasad a "progressive leftist saboteur" who was undermining the agency's work. Loomer critiques earlier this year led to the ouster of national security officials.
On July 28, the Wall Street Journal's opinion section ran two pieces criticizing Prasad, one of which called him a Bernie Sanders acolyte in MAHA drag, referring to the Trump administration's "Make America Healthy Again" movement. Both said he was not basing regulatory decisions on whether drugs helped patients, but on price.
"When he saw some of these sort of smear pieces, he didn't want to be a distraction," Makary said of Prasad's departure in an interview with CNBC on July 30.
George Tidmarsh, a former pharmaceutical executive who was recently appointed to lead the FDA's Center for Drug Evaluation and Research, will also be the acting CBER director, according to the agency's website.
The Department of Health and Human Services, which oversees the FDA, did not announce when the role would be permanently filled.
Prasad, whose departure was announced late on July 29, did not immediately respond to a request for comment.
According to a report in the Politico, Trump on July 29 overruled Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary, and ordered the removal of Prasad.
The FDA on July 28 changed course on Sarepta and said shipments to the main group of patients for the drug could restart.
Other changes under Prasad, who was also the agency's chief medical and science officer, included a new policy limiting the approval for COVID-19 vaccines, and his FDA division also rejected therapies from Replimmune (REPL.O), opens new tab and Capricor Therapeutics (CAPR.O), opens new tab.
Shares of Replimmune nearly doubled in value, while those of Sarepta and Capricor gained 11 percent and 18 percent, respectively on July 30.
Endpoints and STAT news first reported Prasad's departure.
Prasad was a physician who joined the agency from the University of California, San Francisco. He has had stints at the National Cancer Institute and the National Institutes of Health.
The FDA and other health agencies have seen multiple shakeups in recent months, under the leadership of U.S. Health Secretary Robert F. Kennedy Jr.
Prasad's predecessor and longtime vaccine official at the FDA, Peter Marks, was ousted earlier this year, followed by gene therapy head Nicole Verdun.
"While another vacancy and another potential new face add uncertainty, we still think Prasad’s departure is a net positive for the sector as many of our conversations have been overwhelmingly focused on regulatory risk and what he may or may not do," said Leerink analyst Joseph Schwartz.
Related
.JPG)
.JPG)
ADVERTISEMENT
ADVERTISEMENT
E Paper
Video
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login